Carteolol

beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM

Key facts

Carteolol is an ofp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1988. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 2 molecular targets, including ADRB1 and ADRB2. Recorded indications include Hypertensive disorder, Ocular hypertension and Open-angle glaucoma.

• Approval status: ofp (first approved 1988 by the FDA).
• Drug class: beta-Adrenergic Blocker.
• Mechanism of action: Adrenergic beta-Antagonists.
• Molecular targets: ADRB1 and ADRB2 (2 listed in DrugCentral).
• Indications: Hypertensive disorder, Ocular hypertension and Open-angle glaucoma.
• ATC code: C07AA15 (Beta blocking agents, non-selective).
• Molecular formula: C16H24N2O3; molecular weight 292.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Hypertensive disorder
• Ocular hypertension
• Open-angle glaucoma

Off-label uses (1)

• Angina pectoris

Contraindications (14)

• Anaphylaxis
• Asthma
• Cardiogenic shock
• Chronic bronchitis
• Complete atrioventricular block
• Decompensated cardiac failure
• Diabetes mellitus
• Heart failure
• Myasthenia gravis
• Pregnancy, function
• Pulmonary emphysema
• Second degree atrioventricular block
• Severe chronic obstructive pulmonary disease
• Sinus bradycardia

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta-Antagonists
• Established pharmacologic class: beta-Adrenergic Blocker

Molecular targets (2)

Target	Gene	Action	Activity
Beta-1 adrenergic receptor	ADRB1	antagonist	Ki 9.30
Beta-2 adrenergic receptor	ADRB2	antagonist	Ki 9.20

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1988-12-28	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C07AA15	CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, non-selective
S01ED05	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Beta blocking agents
S01ED55	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIGLAUCOMA PREPARATIONS AND MIOTICS › Beta blocking agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Intraocular pressure increased	98.5
Bradycardia	48.7
Hepatitis fulminant	44.0
Shock	33.8
Failed forceps delivery	32.4
Conjunctival hyperaemia	31.6
Choluria	29.8
Hyperkalaemia	29.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Carteolol is on its molecule page.

• Molecular formula: C₁₆H₂₄N₂O₃
• Molecular weight: 292.38 g/mol
• CAS number: 51781-06-7
• InChIKey: LWAFSWPYPHEXKX-UHFFFAOYSA-N
• PubChem CID: 2583

CC(C)(C)NCC(O)COC1=C2CCC(=O)NC2=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Carteolol used for?

DrugCentral lists the following indications for Carteolol: Hypertensive disorder, Ocular hypertension and Open-angle glaucoma.

How does Carteolol work?

Carteolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB1 (antagonist) and ADRB2 (antagonist).

When was Carteolol first approved?

Carteolol was first approved by the FDA in 1988.

What drug class does Carteolol belong to?

Carteolol is in the beta-Adrenergic Blocker class.

What is the chemical formula of Carteolol?

Carteolol has the molecular formula C16H24N2O3 and a molecular weight of 292.38 g/mol.

Sources

• DrugCentral drug card 520 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201002 — compound record and bioactivity
• PubChem CID 2583 — chemical identifiers
• DrugBank DB00521 — drug record
• FDA UNII 8NF31401XG — substance identity
• DailyMed: FDA labels for Carteolol — current prescribing information (label search)
• UniProt P08588 (ADRB1) — target protein
• UniProt P07550 (ADRB2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.